Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Update

Spero Therapeutics, Inc. (NASDAQ:SPRO) was the target of a significant decline in short interest in the month of August. As of August 15th, there was short interest totaling 927,200 shares, adeclineof32.8% from the July 31st total of 1,380,000 shares. Based on an average daily trading volume, of 4,440,000 shares, the short-interest ratio is currently 0.2 days. Based on an average daily trading volume, of 4,440,000 shares, the short-interest ratio is currently 0.2 days.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Spero Therapeutics to a “hold” rating in a research report on Saturday, June 21st. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.00.

Spero Therapeutics Price Performance

SPRO stock opened at $2.02 on Monday. The company has a 50-day moving average of $2.31 and a two-hundred day moving average of $1.60. Spero Therapeutics has a 52-week low of $0.51 and a 52-week high of $3.22. The stock has a market capitalization of $113.69 million, a price-to-earnings ratio of -2.10 and a beta of 1.47.

Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Tuesday, August 12th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.35. Spero Therapeutics had a negative net margin of 110.35% and a negative return on equity of 120.27%. The business had revenue of $14.19 million during the quarter, compared to analysts’ expectations of $11.00 million. Equities analysts expect that Spero Therapeutics will post -1.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SPRO. Stonepine Capital Management LLC bought a new position in shares of Spero Therapeutics in the second quarter valued at approximately $455,000. Invesco Ltd. bought a new position in shares of Spero Therapeutics in the second quarter valued at approximately $43,000. Quadrature Capital Ltd bought a new position in shares of Spero Therapeutics in the second quarter valued at approximately $90,000. XTX Topco Ltd bought a new position in shares of Spero Therapeutics in the second quarter valued at approximately $100,000. Finally, Axxcess Wealth Management LLC bought a new position in shares of Spero Therapeutics in the second quarter valued at approximately $94,000. Institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.